IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability,
antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with
docetaxel in previously-treated locally advanced or metastatic gastric or gastroesophageal
junction (GEJ) adenocarcinoma.